New Care Oncology study results and new website coming The METRICS study was conducted by the London, UK, Care Oncology Clinic between 2013 - 2016 using a perspective analysis comprising 95 patients with a biopsy confirmed Glioblastoma IV brain tumor ("GBM"). Patients could be enrolled into the adjunctive COC Protocol at any time i.e., from presentation of their GBM or at any future time-point if deemed eligible to receive treatment by the consulting COC oncologist. All patients continued to receive their standard of care therapy (surgery, radiation, chemotherapy) and follow up.
The primary endpoint was median overall survival (defined as time from diagnosis until death from any cause):
- Patients receiving the adjunctive COC Protocol had a median overall survival of 26.3 months and a two-year survival of 55.8%.
- Comparative data from Public Health England (Brodbelt et al., 2015), patients receiving standard of care therapy alone had a median overall survival of 14.8 months and a two-year survival of 28.7%; and data from the European Organisation for Research and Treatment of Cancer, a median overall survival of 15.8 months and a two-year survival of 26.5% (Stupp et al., 2005).